Can Can ctD ctDNA be used as as a a Mark arker of of Minimal - - PowerPoint PPT Presentation

▶
can can ctd ctdna be used as as a a mark arker of of
SMART_READER_LITE
LIVE PREVIEW

Can Can ctD ctDNA be used as as a a Mark arker of of Minimal - - PowerPoint PPT Presentation

Jun 30, 2023 141 likes •453 views

Can Can ctD ctDNA be used as as a a Mark arker of of Minimal al R Residual al Di Diseas ase to Di Direct ct Adjuvan Ad ant t Th Therapy i y in Col Colon on Can Cance cer? r? Pashtoon Kasi, MD, MS Assistant Professor

slide-1
SLIDE 1

Can Can ctD ctDNA be used as as a a Mark arker of

  • f

Minimal al R Residual al Di Diseas ase to Di Direct ct Ad Adjuvan ant t Th Therapy i y in Col Colon

  • n Can

Cance cer? r?

Pashtoon Kasi, MD, MS Assistant Professor College of Medicine and Oncology Holden Comprehensive Cancer Center University of Iowa pashtoon-kasi@uiowa.edu @pashtoonkasi

slide-2
SLIDE 2

Disclosures

  • Consultancy/Advisory Board (to institution)
  • Taiho Oncology
  • Ipsen
  • Research/Trial Support (to institution)
  • BMS
  • Celgene
  • Astrazeneca
  • BTG
  • Advanced Accelerator Applications
  • Array Biopharma
slide-3
SLIDE 3
slide-4
SLIDE 4

> 270 abstracts ASCO19

slide-5
SLIDE 5

August 2018 Volume 24, Issue 15

slide-6
SLIDE 6

CtDNA

Diagnosis Minimal Residual Disease Treatment Response Acquired Resistance

slide-7
SLIDE 7
slide-8
SLIDE 8

Can we reliably detect CtDNA in patients with colorectal cancer?

Does it correspond with

  • utcomes

(recurrence)?

slide-9
SLIDE 9
slide-10
SLIDE 10

Analysi sis o s of Plasm sma Cell ell-Fr Free D ee DNA by by Ultrade deep p Seque uenc ncing ng i in Patien ents W s With Stages I I to III III Colorec ectal C Canc ncer er

slide-11
SLIDE 11

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

slide-12
SLIDE 12

Analysi sis o s of Plasm sma Cell ell-Fr Free D ee DNA by by Ultrade deep p Seque uenc ncing ng i in Patien ents W s With Stages I I to III III Colorec ectal C Canc ncer er

slide-13
SLIDE 13
slide-14
SLIDE 14

Circulating t g tumor

  • r

DNA analy lysis is d detects minim imal l resid idual l diseas ease a e and p pred edicts recurren ence i e in pat atien ents with s stage I II colon ca cancer

slide-15
SLIDE 15
slide-16
SLIDE 16

Circulating t g tumor

  • r

DNA analy lysis is d detects minim imal l resid idual l diseas ease a e and p pred edicts recurren ence i e in pat atien ents with s stage I II colon ca cancer

slide-17
SLIDE 17
slide-18
SLIDE 18

Circul ulating ng mut utant DN DNA to a

  • assess

ss tumo mor dynam amic ics

slide-19
SLIDE 19
slide-20
SLIDE 20
slide-21
SLIDE 21
slide-22
SLIDE 22

At diagnosis, ctDNA is a more sensitive biomarker than CEA in colorectal cancer

CtDNA Detection at Diagnosis CEA Detection at Diagnosis

Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer [published online ahead of print May 9, 2019]. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.0528.

Colorectal Reinert et al. JAMA Oncology

slide-23
SLIDE 23

CtDNA+ 3 vs. 6 months of therapy – IDEA FRANCE

slide-24
SLIDE 24

CtDNA+ 3 vs. 6 months of therapy

slide-25
SLIDE 25

Summary/Future Directions

slide-26
SLIDE 26

T4

High risk

N2

Node positive

MSI- High

Mismatch repair deficiency

slide-27
SLIDE 27

T4

High risk

N2

Node positive

MSI- High

Mismatch repair deficiency

slide-28
SLIDE 28
slide-29
SLIDE 29
slide-30
SLIDE 30

Can Can ctD ctDNA be used as as a a Mark arker of

  • f

Minimal al R Residual al Di Diseas ase to Di Direct ct Ad Adjuvan ant t Th Therapy i y in Col Colon

  • n Can

Cance cer? r?

Pashtoon Kasi, MD, MS Assistant Professor College of Medicine and Oncology Holden Comprehensive Cancer Center University of Iowa pashtoon-kasi@uiowa.edu @pashtoonkasi

slide-31
SLIDE 31